<--- Back to Details
First PageDocument Content
Immunosuppressants / Monoclonal antibodies / Disease-modifying antirheumatic drug / Rheumatoid arthritis / TNF inhibitor / Infliximab / Rheumatology / Etanercept / Adalimumab / Arthritis / Tumor necrosis factor alpha / Penicillamine
Date: 2011-03-14 07:22:47
Immunosuppressants
Monoclonal antibodies
Disease-modifying antirheumatic drug
Rheumatoid arthritis
TNF inhibitor
Infliximab
Rheumatology
Etanercept
Adalimumab
Arthritis
Tumor necrosis factor alpha
Penicillamine

DSU sequential TNFs report

Add to Reading List

Source URL: www.nicedsu.org.uk

Download Document from Source Website

File Size: 171,38 KB

Share Document on Facebook

Similar Documents

Pharmacology / Biotechnology / Health care / Recombinant proteins / Pharmaceutical industry / Immunosuppressants / Amgen / Biosimilar / Etanercept / Filgrastim / Hospira / Generic drug

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

Multiple sclerosis / Medicine / Immunology / Clinical medicine / Autoimmune diseases / Neurological disorders / Neurology / Management of multiple sclerosis / Glatiramer acetate / Immunosuppressants / McDonald criteria / Diagnostic criteria for MS

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

DocID: 1rmwo - View Document

Medicine / Immunosuppressants / Immunology / Clinical medicine / Monoclonal antibodies / Cytokines / Therapeutic antibodies / Autoimmune diseases / Infliximab / Anakinra / Adalimumab / Interferon

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

Medicine / Clinical medicine / Immunology / Immunosuppressants / RTT / Biotechnology / Autoimmune diseases / Arthritis / Certolizumab pegol / TNF inhibitor / UCB / Anakinra

UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

DocID: 1rakB - View Document

Medicine / Immunology / Clinical medicine / Health care / Immunosuppressants / Biotechnology / Monoclonal antibodies / Immune system / Immunogenicity / Autoimmunity / Infliximab / Arthritis

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qY7G - View Document